Skip to main content

Table 5 Odds ratios for major bleeding events

From: Bleeding, thrombosis, and anticoagulation in myeloproliferative neoplasms (MPN): analysis from the German SAL-MPN-registry

 

Odds ratio (OR)

95 % CI

Diagnosis

 PV

1.2480

0.6123–2.5439

 ET

0.3440

0.1307–0.9053

 PMF

1.1892

0.5539–2.5531

 Post-PV-MF

2.8235

0.8964–8.8935

 Post-ET-MF

0.6079

0.0788–4.6904

 MPN-U

2.5130

0.6872–9.1897

Thrombotic/thromboembolic event in medical history

2.7083

1.3578–5.4021

Splenomegaly (detected by palpation)

2.2222

1.0095–4.8919

Low platelets (<100/nl)

1.3120

0.5504–3.1275

High platelets (>1000/nl)

1.1874

0.4401–3.2035

ASS

1.1216

0.5539–2.2712

P2Y12 antagonist

2.8292

0.9979–8.0213

Double platelet inhibition

3.0500

0.9589–9.7016

Oral vitamin K antagonist

1.9739

0.7695–5.0634

Rivaroxaban

1.6092

0.1923–13.4665

Heparin

5.6426

1.8360–17.3421

  1. Significant results are in italics